Rolapitant

Drug Profile

Rolapitant

Alternative Names: Rolapitant hydrochloride; SCH-619734; VARUBI; Varuby

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; Schering-Plough; TESARO
  • Class Antiemetics; Ethers; Piperidines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Discontinued Cough; Postoperative nausea and vomiting

Most Recent Events

  • 04 Apr 2017 Tesaro announces intention to launch oral rolapitant in Europe and IV rolapitant in USA in the second half of 2017 (Tesaro form 10-K, February 2017)
  • 28 Feb 2017 Tesaro has patent protection for rolapitant in USA (Tesaro form 10-K, February 2017)
  • 28 Feb 2017 Tesaro has patents pending for rolapitant in multiple foreign jurisdictions (Tesaro form 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top